Brought to you by 
Ultragenyx starts Series A round with $30mm; adds on $15.1mm later
07 Aug 2012
Executive Summary
Ultragenyx Pharmaceutical Inc. (orphan disease therapeutics) raised $30mm through the start of its Series A round. TPG Biotech and Fidelity Biosciences co-led and were joined by HealthCap, Pappas Ventures, and four other investors. TPG, Fidelity, and HealthCap have all taken seats on the company’s board. According to the Form D, Ultragenyx hopes to raise another $15mm before closing out the round.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ultragenyx starts Series A round with $30mm; adds on $15.1mm later
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice